Search Result

Pathways Recommended:	Cell Cycle/DNA Damage

Results for "

G0/G1 phase cell-cycle arrest

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5 alpha Reductase (2) 5-HT Receptor (1) Adenosine Receptor (3) Akt (4) Anaplastic lymphoma kinase (ALK) (1) Androgen Receptor (1) Apoptosis (95) Aryl Hydrocarbon Receptor (1) ATP-binding cassette (ABC) transporters (1) Autophagy (8) Bcl-2 Family (2) Bcr-Abl (2) Btk (1) c-Kit (1) c-Met/HGFR (2) c-Myc (3) Carbonic Anhydrase (1) Casein Kinase (1) Caspase (6) CDK (9) Checkpoint Kinase (Chk) (1) COX (1) Cytochrome P450 (1) Dihydrofolate reductase (DHFR) (2) Dihydroorotate Dehydrogenase (1) DNA Alkylator/Crosslinker (1) DNA Methyltransferase (2) DNA/RNA Synthesis (5) Drug Derivative (1) Drug Metabolite (2) EGFR (8) Endogenous Metabolite (3) Environmental Pollutants (1) Epigenetic Reader Domain (3) Estrogen Receptor/ERR (3) Ferroptosis (1) FGFR (1) FLT3 (7) GLUT (1) HDAC (9) Histamine Receptor (2) Histone Demethylase (1) Histone Methyltransferase (5) HSP (4) Hsp-targeting Chimeras (1) HyT (1) Influenza Virus (2) Interleukin Related (2) Isotope-Labeled Compounds (1) JAK (1) JNK (1) Keap1-Nrf2 (2) Lactate Dehydrogenase (2) LIM Kinase (LIMK) (1) Lipoxygenase (1) LXR (1) MALT1 (1) MDM-2/p53 (4) Methylenetetrahydrofolate Dehydrogenase (MTHFD) (1) Microtubule/Tubulin (1) Mitochondrial Metabolism (2) MMP (1) MNK (1) Molecular Glues (1) mTOR (6) NF-κB (5) Opioid Receptor (1) p38 MAPK (1) PAK (1) Parasite (3) PARP (5) PD-1/PD-L1 (2) PDGFR (1) PGE synthase (1) Phytohormone (1) PI3K (4) PROTACs (1) Raf (2) Reactive Oxygen Species (ROS) (15) Reference Standards (4) SHP2 (1) Sigma Receptor (1) SOD (1) Src (1) STAT (3) Survivin (1) TNF Receptor (1) Topoisomerase (5) Trk Receptor (2) VEGFR (1) Xanthine Oxidase (2)
By Research Areas:	Cancer (114) Cardiovascular Disease (4) Endocrinology (3) Infection (5) Inflammation/Immunology (10) Metabolic Disease (5) Neurological Disease (7)
Click Chemistry:	PROTAC Synthesis (1) Azide (1)

119

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N0837

Veratramine 1 Publications Verification NSC17821; NSC23880	PI3K Akt mTOR Autophagy Apoptosis	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Veratramine (NSC17821; NSC23880) is an orally active inhibitor of the PI3K/Akt/mTOR signaling pathway and a SIGMAR1 modulator. Veratramine induces autophagic apoptosis of tumor cells, arrests the cell cycle at the G0/G1 phase, and inhibits epithelial-mesenchymal transition (EMT)-related proteins to reduce tumor migration. Veratramine reduces spinal cord and sciatic nerve pathological damage in a neuropathy model by inhibiting SIGMAR1 binding to NMDAR and phosphorylation of NMDAR Ser896. Veratramine has anti-tumor proliferation, apoptosis induction, anti-inflammatory and neuroprotective activities, and can be used in the study of cancers such as liver cancer and osteosarcoma, as well as diabetic peripheral neuropathy .

HY-13768

Topotecan Maximum Cited Publications 38 Publications Verification SKF 104864A; NSC 609669	Topoisomerase Autophagy Apoptosis	Cancer
Topotecan (SKF 104864A; NSC 609669) is an orally active and potent Topoisomerase I inhibitor. Topotecan induces cell cycle arrest in G0/G1 and S phases and promotes apoptosis. Topotecan shows anticancer activity .

HY-15221

Methylstat 3 Publications Verification	Apoptosis Histone Demethylase MDM-2/p53	Cardiovascular Disease Cancer
Methylstat is a potent histone demethylases inhibitor. Methylstat shows anti-proliferative activity with low cytotoxicity. Methylstat induces apoptosis and cell cycle arrest at G0/G1 phase. Methylstat increases the expression of p53 and p21 protein levels. Methylstat inhibits angiogenesis induced by various cytokines. Methylstat can be used as a chemical probe for addressing its role in angiogenesis .

HY-B1165

Cyproheptadine (hydrochloride sesquihydrate) 3 Publications Verification	p38 MAPK Checkpoint Kinase (Chk) Histamine Receptor 5-HT Receptor CDK PARP Apoptosis	Cancer
Cyproheptadine hydrochloride sesquihydrate acts as a p38 MAP kinase activator, CHK2 activator, histamine H1 receptor inhibitor and serotonin receptor inhibitor. Cyproheptadine hydrochloride sesquihydrate mediates cell cycle arrest via G1 phase arrest, G1/S transition arrest, G0/G1 phase arrest, reduced expression of cyclins D1/D2/D3, upregulated expression of HBP1, p16, p21, p27, and decreased phosphorylation of retinoblastoma protein. Cyproheptadine hydrochloride sesquihydrate induces Apoptosis by increasing PARP and cleaved PARP, as well as activating the mitochondrial caspase pathway. Cyproheptadine hydrochloride sesquihydrate inhibits tumor growth with extremely low toxicity to normal cells. Cyproheptadine hydrochloride sesquihydrate can be used in research related to hepatocellular carcinoma, multiple myeloma and acute myeloid leukemia .

HY-131906

JAK2-IN-7	JAK FLT3 Apoptosis	Cancer
JAK2-IN-7 is a selective JAK2 inhibitor with IC₅₀s of 3, 11.7, and 41 nM for JAK2, SET-2, and Ba/F3 ^V617F cells, respectively. JAK2-IN-7 possesses >14-fold selectivity over JAK1, JAK3, FLT3. JAK2-IN-7 stimulates cell cycle arrest in the G0/G1 phase and induces tumor cellapoptosis. Antitumor activities .

HY-17026E

Gemcitabine triphosphate trisodium dFdCTP trisodium	Drug Metabolite DNA/RNA Synthesis Apoptosis	Cancer
Gemcitabine triphosphate (dFdCTP) trisodium is the active metabolite of Gemcitabine (HY-17026). The mechanism of Gemcitabine triphosphate trisodium cell-killing is its competition with cytidine triphosphate during DNA replication, which results in the inhibition of chain elongation. Gemcitabine triphosphate trisodium shows a K_i of 11.2 μM against DNA polymerase α and 14.4 μM against DNA polymerase ε. Gemcitabine triphosphate trisodium partially inhibits dCMP deaminase and acts as a substrate for DNA synthesis to incorporate into cellular DNA and RNA. Gemcitabine triphosphate trisodium disrupts DNA and RNA synthesis, arrests cell cycle in G0/G1 and S phases, triggers apoptosis, reduces tumor cell proliferation. Gemcitabine triphosphate trisodium can be used for the research of pancreatic cancer and non-small cell lung cancer .

HY-N7844

N6-Benzyladenosine Benzyladenosine	Apoptosis Adenosine Receptor	Inflammation/Immunology Cancer
N6-Benzyladenosine is an adenosine receptor agonist, has a cytoactive activity. N6-Benzyladenosine arrests cell cycle at G0/G1 phase and induces cell apoptosis. N6-Benzyladenosine also exerts inhibitory effect on T. gondii adenosine kinase and glioma ^- .

HY-N0440

Germacrone 2 Publications Verification	Influenza Virus NF-κB 5 alpha Reductase Keap1-Nrf2 Lactate Dehydrogenase Apoptosis	Infection Neurological Disease Inflammation/Immunology Endocrinology Cancer
Germacrone is a sesquiterpene compound with multiple biological activities. Germacrone inhibits the H1N1 and H3N2 inﬂuenza A virus and the inﬂuenza B virus. Germacrone blocks the progressionof arthritis by regulating Th1/Th2 balance and inhibiting NF-κB signaling. Germacrone can arrest the cell cycle at G0/G1 and G2/M phases and induce apoptosis in breast cancer cells. Germacrone inhibits 5α-reductase and has anti-androgenic effect. Germacrone has neuroprotective functions and can be used for the study of traumatic brain injury (TBI). Germacrone also has antioxidant activity .

HY-146980

GLUT4-IN-2	Apoptosis GLUT	Cancer
GLUT4-IN-2 is a potent and selective GLUT4 inhibitor with IC₅₀s of 11.4 µM and 6.8 µM for GLUT1 and GLUT4, respectively. GLUT4-IN-2 induces cell apoptosis and cell cycle arrest at G0/G1phase. GLUT4-IN-2 shows potent antitumor activity .

HY-17026A

Gemcitabine triphosphate dFdCTP	Drug Metabolite DNA/RNA Synthesis Apoptosis	Cancer
Gemcitabine triphosphate (dFdCTP) is the active metabolite of Gemcitabine (HY-17026). The mechanism of Gemcitabine triphosphate cell-killing is its competition with cytidine triphosphate during DNA replication, which results in the inhibition of chain elongation. Gemcitabine triphosphate shows a K_i of 11.2 μM against DNA polymerase α and 14.4 μM against DNA polymerase ε. Gemcitabine triphosphate partially inhibits dCMP deaminase and acts as a substrate for DNA synthesis to incorporate into cellular DNA and RNA. Gemcitabine triphosphate disrupts DNA and RNA synthesis, arrests cell cycle in G0/G1 and S phases, triggers apoptosis, reduces tumor cell proliferation. Gemcitabine triphosphate can be used for the research of pancreatic cancer and non-small cell lung cancer .

HY-114414

HDACs/mTOR Inhibitor 1 1 Publications Verification	HDAC mTOR Apoptosis	Cancer
HDACs/mTOR Inhibitor 1 is a dual HDACs and mTOR inhibitor, with IC₅₀s of 0.19 nM, 1.8 nM, 1.2 nM for HDAC1, HDAC6, mTOR, respectively. HDACs/mTOR Inhibitor 1 stimulates cell cycle arrest in G0/G1 phase and induces tumor cell apoptosis with low toxicity in vivo. HDACs/mTOR Inhibitor 1 can be used in the research of hematologic malignancies .

HY-124211

Dibenzo(a,i)pyrene	Environmental Pollutants MDM-2/p53 Aryl Hydrocarbon Receptor	Cancer
Dibenzo (a,i) pyrene is a polycyclic aromatic hydrocarbon and also a carcinogenic ligand of the TCDD (Ah) receptor. Dibenzo (a,i) pyrene binds to the TCDD (Ah) receptor in rat liver. Dibenzo (a,i) pyrene induces DNA adduct formation and upregulates the protein levels of p53 and p21 ^WAF1 in diploid lung fibroblasts. Dibenzo (a,i) pyrene alters the cell cycle distribution of diploid lung fibroblasts, increasing the proportion of cells in the S phase, decreasing the proportions of cells in the G0/G1 and G2/M phases, and causing S phase delay/arrest. Dibenzo (a,i) pyrene is applicable for cancer research .

HY-10815

σ1 Receptor antagonist-1 1 Publications Verification	Sigma Receptor Apoptosis	Neurological Disease Cancer
σ1 Receptor antagonist-1 is a highly potent and selective sigma 1 receptor antagonist (pK_i=10.28). σ1 Receptor antagonist-1 inhibits cell growth, arrests cell cycle at G0/G1 phase and induces apoptosis of MCF-7/ADR cells .

HY-173557

PRMT7-IN-2	Histone Methyltransferase Apoptosis	Cancer
PRMT7-IN-2 (A33) is a selective PRMT7 inhibitor with an IC₅₀ of 0.50 μM. PRMT7-IN-2 arrests cell cycle at G0/G1 phase, induces cell apoptosis, and inhibits cell growth in vivo and in vitro. PRMT7-IN-2 decreases the monomethylarginine level of PRMT7, increases expression of epithelial marker (E-cadherin, and reduces expression of mesenchymal markers such as N-cadherin, Vimentin, and ZEB2 .

HY-174371

INNO-220	Molecular Glues Casein Kinase MDM-2/p53 MALT1	Neurological Disease Cancer
INNO-220 is an orally active, CRBN-dependent molecular glue degrader targeting CK1α. INNO-220 induces cell cycle arrest at G0/G1 phase and triggers apoptosis by degrading CK1α. INNO-220 disrupts the assembly and function of the CARD11/BCL10/MALT1 complex, thereby inhibiting NF-κB signaling in stimulated T cells and lymphoma cells that harbor an activating mutation in CARD11. INNO-220 provides a new direction for lymphoma research.

HY-N1930

(-)-Hinesol Hinesol	Apoptosis	Cancer
(-)-Hinesol (Hinesol) is a potent anticancer agent. (-)-Hinesol induces apoptosis and cell cycle arrest at G0/G1 phase. (-)-Hinesol downregulates MEK/ERK pathway and NF-κB pathway and mediates theexpression of cyclin D1, Bax and Bcl-2. (-)-Hinesol has the potential for the research of non–small cell lung cancer .

HY-149891

HSP90-IN-23	HSP	Cancer
HSP90-IN-23 (Comp 12-1) is an inhibitor of heat shock protein 90(HSP90) with an IC₅₀ of 9 nM. HSP90-IN-23 induces apoptosis of tumor cells and arrests the tumor cell cycle in G0/G1 phase. HSP90-IN-23 can be used for cancer research .

HY-149132

Dendrogenin A DDA	LXR	Cancer
Dendrogenin A (DDA) is a ligand for liver X receptor (LXR), that induces the expression of sodium/iodine symporter, and increases iodine uptake. Dendrogenin A induces cell differentiation of MCF-7, and reactivates the function of lactating cells. Dendrogenin A induces the expressions of the TSH receptor, thyroid peroxidase, and thyroglobulin, and affects thyroid hormone generation. Dendrogenin A exhibits cytotoxicity in cancer cell B-CPAP and 8505c with IC₅₀ of 4.1 and 6.2 µM. Dendrogenin A arrests the cell cycle at G0/G1 phase .

HY-164384

DFX117	PI3K Akt mTOR Apoptosis	Cancer
DFX117 is a selective, orally active inhibitor for PI3Kα and c-Met tyrosine kinase. DFX117 inhibits PI3K/Akt/mTOR pathway, inhibits the proliferation of NCI-H1975, NCI-H1993, and HCC827 with IC₅₀s 0.02-0.08 µM. DFX117 arrests cell cycle at G0/G1 phase, induces apoptosis in A549 and NCI-H1975. DFX117 exhibits antitumor efficacy in mice .

HY-174129

TM471-1	Btk Apoptosis	Cancer
TM471-1 is an orally active and covalent Bruton's tyrosine kinase (BTK) inhibitor with IC₅₀ values of 1.3 nM (BTK ^WT), >40,000 nM (BTK ^C481S), 7.9 nM (TEC) and 12.4 nM (TXK). TM471-1 inhibits cell growth in vivo and in vitro, arrests cell cycle at G0/G1 phase and induces cell apoptosis .

HY-124261

Sampangine	Apoptosis	Cancer
Sampangine is an alkaloid that induces apoptosis by inducing cell cycle arrest in the G0/G1 phase. Sampangine can inhibit the biosynthesis of heme .

HY-144733

ERα antagonist 1	Estrogen Receptor/ERR Apoptosis	Cancer
ERα antagonist 1 (Compound 19d) is a potent, selective, covalent estrogen receptor α (ERα) antagonist. ERα antagonist 1 induces apoptosis and cell cycle G0/G1 phase arrest in MCF-7 cells .

HY-N16567

Acrofolione A	Apoptosis Caspase PARP Survivin	Cancer
Acrofolione A is an acetophenone dimer isolated from Acronychia pendunculata with anticancer effects. Acrofolione A induces G0/G1 phase cell cycle arrest and apoptosis in human NALM-6 pre-B cell leukaemia cells. Acrofolione A can be used for leukaemia research .

HY-10638

AP23464	c-Kit Apoptosis	Cancer
AP23464 is an ATP-based inhibitor for Kit, that inhibits the phosphorylation of Kit wildtype and mutants, with IC₅₀ of 5-85 nM. AP23464 inhibits the proliferation of Kit mutated cells (IC₅₀ is 3-20 nM), arrests the cell cycle at G0/G1 phase, and induces apoptosis in Kit mutated cells .

HY-129592

p-Tolylmaleimide	Apoptosis	Cancer
p-Tolylmaleimide (compound 9) is a naphthalimide derivative that has cytotoxic effects on cancer cells. p-Tolylmaleimide can arrest the cell cycle of human acute myeloid leukemia cells K562 in the sub-G0/G1 phase and induce apoptosis .

HY-N12044

Asparanin A	Apoptosis	Cancer
Asparanin A is an apoptosis inducer with anticancer activity. Asparanin A induces cell cycle arrest in the G0/G1 phase through mitochondria and PI3K/AKT signaling pathways, inhibiting cancer cell growth. Asparanin A also demonstrated in vivo efficacy in a mouse xenograft model of Ishikawa endometrial carcinoma, significantly inhibiting tumor growth .

HY-122359A

rel-Levormeloxifene rel-L-Centchroman; Ormeloxifene	Estrogen Receptor/ERR Apoptosis Reactive Oxygen Species (ROS)	Cancer
rel-Levormeloxifene (rel-L-Centchroman) is the relative configuration of Levormeloxifene (HY-122359). rel-Levormeloxifene is a selective estrogen receptor modulator (SERM). rel-Levormeloxifene inhibits proliferation of leukemia cells with IC₅₀ about 7 μM, arrests cell cycle at G0/G1 phase, and induces apoptosis. rel-Levormeloxifene induces differentation of myelogenesis leukemia, and enhances ROS production in K562 cells .

HY-163535

J208	HDAC DNA Methyltransferase Apoptosis	Inflammation/Immunology Cancer
J208 is a dual inhibitor for histone deacetylase (HDAC) and DNA methyltransferase (DNMT). J208 inhibits proliferation of cancer cells, as well as the migration/invasion of triple-negative breast cancer (TNBC) cells. J208 induces apoptosis, arrests the cell cycle at G0/G1 phase. J2008 activates the innate immune signalling pathway in TNBC, by inducing the expression of endogenous retroviruses (ERVs) .

HY-168205

HSP90-IN-33	HSP Apoptosis	Cancer
HSP90-IN-33 (compound 24e) is a potent Hsp90 inhibitor with K_d values of ≥200, 7.3 µM for Hsp90α, Hsp90β, respectively. HSP90-IN-33 induces apoptosis and cell cycle arrest at G0/G1 phase. HSP90-IN-33 decreases the protein expression of ERα, CDK4 and Akt .

HY-150688

JAK3-IN-13	JNK	Cancer
JAK3-IN-13 (compound 12n) is a potent, selective and orally active JAK3 inhibitor with IC₅₀ values of 4728, 2039, 8, 365 nM for NK1, JNK2, JNK3, Tyk2, respectively. JAK3-IN-13 shows antiproliferative activity. JAK3-IN-13 induces cell cycle arrest at G0/G1 phase. JAK3-IN-13 shows antitumor activity .

HY-179124

Apoptosis inducer 52	Apoptosis Caspase	Cancer
Apoptosis inducer 52 is a derivative of flutamide that induces apoptosis in prostate cancer cells. Apoptosis inducer 52 promotes apoptosis by activating both intrinsic and extrinsic apoptotic pathways, without generating reactive oxygen species (ROS). Apoptosis inducer 52 triggers caspase 3/7 activity and the externalization of phosphatidylserine, leading to cell cycle arrest at the G₀/G₁ phase. Apoptosis inducer 52 can be used for the research of androgen receptor (AR)-dependent and -independent prostate cancers and leukemia .

HY-115906

K783-0308	FLT3 MNK Apoptosis	Cancer
K783-0308 is a potent and selective dual inhibitor of FLT3 and MNK2 with IC₅₀ values of 680 and 406 nM, respectively. K783-0308 inhibits the growth of MOLM-13 (IC₅₀=10.5 µM) and MV-4-11 (IC₅₀=10.4 µM) cells. K783-0308 promotes acute myeloid leukemia (AML) cell apoptosis and cell cycle arrests in the G0/G1 phase .

HY-178350

MFDCH016	CDK HDAC Apoptosis Histamine Receptor	Cancer
MFDCH016 is a potent HDAC1/6 (IC₅₀ = 38/59 nM) and CDK4/6 (IC₅₀ = 680/720 nM) inhibitor. MFDCH016 induces apoptosis and cell cycle arrest in G2/M and G0/G1 phases in MCF-7 cells. MFDCH016 can modulate the HDAC-p21-CDK signaling pathway, increasing the levels of acetylated H3 and p21. MFDCH016 can be used for the study of breast cancer .

HY-152146

HDAC-IN-50	Apoptosis FGFR HDAC	Cancer
HDAC-IN-50 is a potent and orally active FGFR and HDAC dual inhibitor with IC₅₀ values of 0.18, 1.2, 0.46, 1.4, 1.3, 1.6, 2.6, 13 nM for FGFR1, FGFR2, FGFR3, FGFR4, HDAC1, HDAC2, HDAC6, HDAC8, respectively. HDAC-IN-50 induces Apoptosis and cell cycle arrest at G0/G1 phase. HDAC-IN-50 decreases the expression of pFGFR1, pERK, pSTAT3. HDAC-IN-50 shows anti-tumor activity .

HY-178941

DHODH-IN-32	Dihydroorotate Dehydrogenase Apoptosis Caspase Reactive Oxygen Species (ROS)	Cancer
DHODH-IN-32 (Compound A1) is a DHODH inhibitor. DHODH-IN-32 shows significant cytotoxicity against NCI-60 cell lines, especially being sensitive to breast cancer, prostate cancer and leukemia cell lines. DHODH-IN-32 can induce cell apoptosis by activating the Caspase pathway. DHODH-IN-32 causes G0/G1 phase cell cycle arrest and inhibits cellular metabolism by ROS. DHODH-IN-32 exhibits significant anti-tumor properties in mouse breast cancer models. DHODH-IN-32 can be used for the study of breast cancer .

HY-159897

PAK4-IN-5	PAK LIM Kinase (LIMK) Apoptosis Reactive Oxygen Species (ROS)	Cancer
PAK4-IN-5 (Compound 12i) is a PAK4 inhibitor (IC₅₀: 7.68 nM for PAK4, 1872.01 nM for PAK1). PAK4-IN-5 binds to PAK4 stably via multiple interactions. PAK4-IN-5 inhibits the proliferation and the migratory potential of MDA-MB-231 cells by inhibiting the phosphorylation of PAK4 and LIMK1. PAK4-IN-5 arrests cell cycle in the G0/G1 phase, induces apoptosis and ROS production. LD₅₀: >500 mg/kg for mice (p.o.) .

HY-13768C

Topotecan hydrochloride hydrate SKF 104864A hydrochloride hydrate; NSC 609669 hydrochloride hydrate	Topoisomerase Apoptosis Autophagy	Cancer
Topotecan hydrochloride hydrate is an orally active and potent Topoisomerase I inhibitor. Topotecan hydrochloride hydrate induces cell cycle arrest in G0/G1 and S phases and promotes apoptosis. Topotecan hydrochloride hydrate shows anticancer activity .

HY-162416

CDK7-IN-27	CDK	Cancer
CDK7-IN-27 (Compound 37) is a selective inhibitor for cyclin-dependent kinase 7 (CDK7), with K_i of 3 nM. CDK7-IN-27 arrests the cell cycle at G0/G1 phase .

HY-155544

Antitumor agent-111	c-Met/HGFR	Cancer
Antitumor agent-111 (compound 46) is an c-Met kinase inhibitor (IC₅₀=46 nM) with antitumor and antiproliferative activity. Antitumor agent-111 arrests cell cycle at G0/G1 phase, and induces apoptosis .

HY-147801

Topoisomerase IIα-IN-3	Topoisomerase Apoptosis	Cancer
Topoisomerase IIα-IN-3 (Compound 12c) is a DNA intercalative topoisomerase-IIα inhibitor. Topoisomerase IIα-IN-3 arrests cell cycle at the G0/G1 phase and induces apoptosis .

HY-145762

YM281	Apoptosis Histone Methyltransferase	Cancer
YM281 is a potent EZH2 inhibitor. YM281 induces cell apoptosis and cell cycle arrest at the G0/G1 phase. YM281 shows antitumor effects in vivo. YM281 has the potential for the research of lymphoma .

HY-155503

Antitumor agent-103	Apoptosis	Cancer
Antitumor agent-103 (compound 24l) is an apoptosis inducer with antiproliferative and anti-clony formation activities. Antitumor agent-103 arrests cell cycle at G0/G1 phase, enhances NO production, and exhibits anti-tumor activity .

HY-149063

Antitumor agent-92	Apoptosis	Cancer
Antitumor agent-92, an Icaritin (HY-N0678) derivative, causes arrest at the G0/G1 phase in the cell cycle and induces cell apoptosis. Antitumor agent-92 has the potential for hepatocellular carcinoma (HCC) research .

HY-163722

EGFR/DHFR-IN-1	EGFR Dihydrofolate reductase (DHFR)	Cancer
EGFR/DHFR-IN-1 (Compound 10e) is a dual inhibitor of EGFR and DHFR with IC₅₀s of 0.151 and 0.541 µM, respectively. EGFR/DHFR-IN-1 arrests the cell cycle at both G0-G1 and S phases .

HY-159096

Apoptosis inducer 21	Apoptosis	Cancer
Apoptosis inducer 21 (Compound 5h) inhibits the proliferation of lung cancer cell H69AR with an IC₅₀ of 1.58 μM. Apoptosis inducer 21 arrests the cell cycle at G0/G1 phase, induces apoptosis in H69AR .

HY-146040

Anticancer agent 47	Apoptosis	Cancer
Anticancer agent 47 (compound 4j) is a potent anticancer agent. Anticancer agent 47 shows antiproliferative activities. Anticancer agent 47 induces apoptosis and cell cycle arrest at G0/G1 phase. Anticancer agent 47 shows shows antitumor activities in vivo .

HY-146063

Anticancer agent 54	Apoptosis	Cancer
Anticancer agent 54 is a potent anticancer agent. Anticancer agent 54 shows antiproliferative activity. Anticancer agent 54 induces apoptosis and cell cycle arrest at G0/G1 phases. Anticancer agent 54 shows anticancer activity depends on DNA intercalation and ROS generation .

HY-P11173

Cr-ACP1	DNA Alkylator/Crosslinker Apoptosis	Cancer
Cr-ACP1 is an anti-cancerous peptide. Cr-ACP1 binds to DNA, inducing cell cycle arrest in the G0-G1 phase, leading to the initiation of Apoptosis mechanisms. Cr-ACP1 exhibits anticancer effects against colon cancer and epidermoid carcinoma .

HY-165064

C2 L-Erythro ceramide (d18:1/2:0) L-Erythro cer(d18:1/2:0); N-Acetyl-L-erythro-sphingosine; Acetyl-L-erythro-sphingosine	Apoptosis	Cancer
C2 L-Erythro ceramide (d18:1/2:0) is a cell-permeable sphingolipid. C2 L-Erythro ceramide (d18:1/2:0) induces cell cycle arrest in the G0/G1 phase and inhibits cell growth .

HY-170323

4-TM.P	Apoptosis	Cancer
4-TM.P binds to the minor groove of DNA, inhibits proliferation of cancer cell K562 with an IC₅₀ of 25 µM, arrests the cell cycle at G0/G1 phase, and induces apoptosis in cell K562. 4-TM.P can be used in anti-leukemia research .

Cat. No.	Product Name	Target	Research Area

HY-P11173

Cr-ACP1	DNA Alkylator/Crosslinker Apoptosis	Cancer
Cr-ACP1 is an anti-cancerous peptide. Cr-ACP1 binds to DNA, inducing cell cycle arrest in the G0-G1 phase, leading to the initiation of Apoptosis mechanisms. Cr-ACP1 exhibits anticancer effects against colon cancer and epidermoid carcinoma .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0837

Veratramine 1 Publications Verification NSC17821; NSC23880	Alkaloids Piperidine Alkaloids Structural Classification other families Classification of Application Fields Plants Disease Research Fields Source Classification Cancer	PI3K Akt mTOR Autophagy Apoptosis
Veratramine (NSC17821; NSC23880) is an orally active inhibitor of the PI3K/Akt/mTOR signaling pathway and a SIGMAR1 modulator. Veratramine induces autophagic apoptosis of tumor cells, arrests the cell cycle at the G0/G1 phase, and inhibits epithelial-mesenchymal transition (EMT)-related proteins to reduce tumor migration. Veratramine reduces spinal cord and sciatic nerve pathological damage in a neuropathy model by inhibiting SIGMAR1 binding to NMDAR and phosphorylation of NMDAR Ser896. Veratramine has anti-tumor proliferation, apoptosis induction, anti-inflammatory and neuroprotective activities, and can be used in the study of cancers such as liver cancer and osteosarcoma, as well as diabetic peripheral neuropathy .

HY-17026E

Gemcitabine triphosphate trisodium dFdCTP trisodium	Structural Classification Natural Products Classification of Application Fields Endogenous metabolite Disease Research Fields Source Classification Cancer	Drug Metabolite DNA/RNA Synthesis Apoptosis
Gemcitabine triphosphate (dFdCTP) trisodium is the active metabolite of Gemcitabine (HY-17026). The mechanism of Gemcitabine triphosphate trisodium cell-killing is its competition with cytidine triphosphate during DNA replication, which results in the inhibition of chain elongation. Gemcitabine triphosphate trisodium shows a K_i of 11.2 μM against DNA polymerase α and 14.4 μM against DNA polymerase ε. Gemcitabine triphosphate trisodium partially inhibits dCMP deaminase and acts as a substrate for DNA synthesis to incorporate into cellular DNA and RNA. Gemcitabine triphosphate trisodium disrupts DNA and RNA synthesis, arrests cell cycle in G0/G1 and S phases, triggers apoptosis, reduces tumor cell proliferation. Gemcitabine triphosphate trisodium can be used for the research of pancreatic cancer and non-small cell lung cancer .

HY-N2392

Kukoamine A 1 Publications Verification	Cardiovascular Disease Alkaloids Structural Classification other families Classification of Application Fields Other Alkaloids Phenols Polyphenols Plants Disease Research Fields Source Classification	Parasite Lipoxygenase Opioid Receptor Apoptosis Autophagy Reactive Oxygen Species (ROS) Interleukin Related TNF Receptor PGE synthase COX
Kukoamine A, a spermine alkaloid, is an orally active and brain-penetrant component found in the root barks of Lycium chinense (L. chinense) Miller. Kukoamine A inhibits purified Crithidia fasciculata trypanothione reductase and soybean lipoxygenase, activates μ-opioid receptor. Kukoamine A can inhibt cancer cell proliferation, migration and invasion, cause G0/G1 phase cell cycle arrest and induce apoptosis. Kukoamine A exerts neuroprotective effect and can induce autophagy . Kukoamine A inhibits LPS (HY-D1056)-induced NO, ROS, PGE₂, TNF-α, IL-1β, IL-6 production and COX-2 activity. Kukoamine A reverses palmitic acid-induced insulin resistance, lipid accumulation, and oxidative stress via downregulation of Srebp-1c. Kukoamine A can be used for the research of cancer, infection, inflammation, metabolic and neurological disease, such as glioblastoma and Parkinson's disease .

HY-N7844

N6-Benzyladenosine Benzyladenosine	Natural Products Classification of Application Fields Umbelliferae Plants Phytohormone Eupatorium buniifolium Hook. & Arn. Inflammation/Immunology Disease Research Fields Cytokinin Source Classification Cancer Agricultural Research	Apoptosis Adenosine Receptor
N6-Benzyladenosine is an adenosine receptor agonist, has a cytoactive activity. N6-Benzyladenosine arrests cell cycle at G0/G1 phase and induces cell apoptosis. N6-Benzyladenosine also exerts inhibitory effect on T. gondii adenosine kinase and glioma ^- .

HY-N0440

Germacrone 2 Publications Verification	Infection Classification of Application Fields Terpenoids Sesquiterpenes Plants Curcuma longa Disease Research Fields Source Classification Zingiberaceae	Influenza Virus NF-κB 5 alpha Reductase Keap1-Nrf2 Lactate Dehydrogenase Apoptosis
Germacrone is a sesquiterpene compound with multiple biological activities. Germacrone inhibits the H1N1 and H3N2 inﬂuenza A virus and the inﬂuenza B virus. Germacrone blocks the progressionof arthritis by regulating Th1/Th2 balance and inhibiting NF-κB signaling. Germacrone can arrest the cell cycle at G0/G1 and G2/M phases and induce apoptosis in breast cancer cells. Germacrone inhibits 5α-reductase and has anti-androgenic effect. Germacrone has neuroprotective functions and can be used for the study of traumatic brain injury (TBI). Germacrone also has antioxidant activity .

HY-17026A

Gemcitabine triphosphate dFdCTP	Structural Classification Natural Products Classification of Application Fields Endogenous metabolite Disease Research Fields Source Classification Cancer	Drug Metabolite DNA/RNA Synthesis Apoptosis
Gemcitabine triphosphate (dFdCTP) is the active metabolite of Gemcitabine (HY-17026). The mechanism of Gemcitabine triphosphate cell-killing is its competition with cytidine triphosphate during DNA replication, which results in the inhibition of chain elongation. Gemcitabine triphosphate shows a K_i of 11.2 μM against DNA polymerase α and 14.4 μM against DNA polymerase ε. Gemcitabine triphosphate partially inhibits dCMP deaminase and acts as a substrate for DNA synthesis to incorporate into cellular DNA and RNA. Gemcitabine triphosphate disrupts DNA and RNA synthesis, arrests cell cycle in G0/G1 and S phases, triggers apoptosis, reduces tumor cell proliferation. Gemcitabine triphosphate can be used for the research of pancreatic cancer and non-small cell lung cancer .

HY-N1930

(-)-Hinesol Hinesol	Structural Classification Terpenoids Sesquiterpenes Plants Compositae Erythrina sigmoidea Hua	Apoptosis
(-)-Hinesol (Hinesol) is a potent anticancer agent. (-)-Hinesol induces apoptosis and cell cycle arrest at G0/G1 phase. (-)-Hinesol downregulates MEK/ERK pathway and NF-κB pathway and mediates theexpression of cyclin D1, Bax and Bcl-2. (-)-Hinesol has the potential for the research of non–small cell lung cancer .

HY-149132

Dendrogenin A DDA	Triterpenes Terpenoids Endogenous metabolite Source Classification	LXR
Dendrogenin A (DDA) is a ligand for liver X receptor (LXR), that induces the expression of sodium/iodine symporter, and increases iodine uptake. Dendrogenin A induces cell differentiation of MCF-7, and reactivates the function of lactating cells. Dendrogenin A induces the expressions of the TSH receptor, thyroid peroxidase, and thyroglobulin, and affects thyroid hormone generation. Dendrogenin A exhibits cytotoxicity in cancer cell B-CPAP and 8505c with IC₅₀ of 4.1 and 6.2 µM. Dendrogenin A arrests the cell cycle at G0/G1 phase .

HY-N0440R

Germacrone (Standard)	Structural Classification Terpenoids Sesquiterpenes Plants Curcuma longa Source Classification Zingiberaceae	Reference Standards Influenza Virus NF-κB 5 alpha Reductase Keap1-Nrf2 Lactate Dehydrogenase Apoptosis
Germacrone (Standard) is an analytical standard of Gemmacrone (HY-N0440). This product is intended for research and analytical applications. Germacrone (Standard) is a sesquiterpene compound with multiple biological activities. Germacrone (Standard) inhibits the H1N1 and H3N2 inﬂuenza A viruses and the inﬂuenza B virus. Germacrone (Standard) blocks the progressionof arthritis by regulating Th1/Th2 balance and inhibiting NF-κB signaling. Germacrone (Standard) can arrest the cell cycle at G0/G1 and G2/M phases and induce apoptosis in breast cancer cells. Germacrone (Standard) inhibits 5α-reductase and has anti-androgenic effect. Germacrone (Standard) has neuroprotective functions and can be used for the study of traumatic brain injury (TBI). Germacrone (Standard) also has antioxidant activity .

HY-Y0106

2,6-Dihydroxyacetophenone	Classification of Application Fields Ketones, Aldehydes, Acids Phenols Polyphenols Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	mTOR Xanthine Oxidase Apoptosis
2,6-Dihydroxyacetophenone, a polyphenolic derivative of Acetophenone (HY-Y0989), is an orally active mTOR inhibitor. 2,6-Dihydroxyacetophenone shows antioxidant activity. 2,6-Dihydroxyacetophenone inhibits cell growth and proliferation in CRC cells. 2,6-Dihydroxyacetophenone arrests at G0/G1 phase of cell cycle, induces apoptosis and suppresses cell migration in CRC cells. 2,6-Dihydroxyacetophenone inhibits xanthine oxidase (XOD) with an IC₅₀ of 1.24 mM. 2,6-dihydroxyacetophenone improves uric acid metabolism in hyperuricemia mice, reduces plasma cholesterol in hypercholesterolemic rats, and inhibits lipid accumulation in HFD-induced obese mice. 2,6-Dihydroxyacetophenone can be used for the study of colorectal cancer (CRC), hyperuricemia and hypercholesterolemia .

HY-N0837R

Veratramine (Standard) NSC17821 (Standard); NSC23880 (Standard)	Alkaloids Piperidine Alkaloids Structural Classification other families Plants Source Classification	Reference Standards PI3K Akt mTOR Autophagy Apoptosis
Veratramine (NSC17821; NSC23880) (Standard) is the analytical standard of Veratramine (HY-N0837). This product is intended for research and analytical applications. Veratramine (NSC17821; NSC23880) is an orally active inhibitor of the PI3K/Akt/mTOR signaling pathway and a SIGMAR1 modulator. Veratramine induces autophagic apoptosis of tumor cells, arrests the cell cycle at the G0/G1 phase, and inhibits epithelial-mesenchymal transition (EMT)-related proteins to reduce tumor migration. Veratramine reduces spinal cord and sciatic nerve pathological damage in a neuropathy model by inhibiting SIGMAR1 binding to NMDAR and phosphorylation of NMDAR Ser896. Veratramine has anti-tumor proliferation, apoptosis induction, anti-inflammatory and neuroprotective activities, and can be used in the study of cancers such as liver cancer and osteosarcoma, as well as diabetic peripheral neuropathy .

HY-124261

Sampangine	Alkaloids Other Alkaloids Cananga odorata Plants Annonaceae Source Classification	Apoptosis
Sampangine is an alkaloid that induces apoptosis by inducing cell cycle arrest in the G0/G1 phase. Sampangine can inhibit the biosynthesis of heme .

HY-N16567

Acrofolione A	Structural Classification Acronychia haplophylla Ketones, Aldehydes, Acids Rutaceae Plants Source Classification	Apoptosis Caspase PARP Survivin
Acrofolione A is an acetophenone dimer isolated from Acronychia pendunculata with anticancer effects. Acrofolione A induces G0/G1 phase cell cycle arrest and apoptosis in human NALM-6 pre-B cell leukaemia cells. Acrofolione A can be used for leukaemia research .

HY-N12044

Asparanin A	Structural Classification Liliaceae Plants Steroids Source Classification Asparagus officinalis L.	Apoptosis
Asparanin A is an apoptosis inducer with anticancer activity. Asparanin A induces cell cycle arrest in the G0/G1 phase through mitochondria and PI3K/AKT signaling pathways, inhibiting cancer cell growth. Asparanin A also demonstrated in vivo efficacy in a mouse xenograft model of Ishikawa endometrial carcinoma, significantly inhibiting tumor growth .

HY-N3764

Diosbulbin C	Terpenoids Diterpenoids Plants Dioscorea bulbifera Linn. Dioscoreaceae Source Classification	Akt Dihydrofolate reductase (DHFR) Endogenous Metabolite
Diosbulbin C is a diterpene lactone component, which can be extracted from traditional Chinese medicine Dioscorea bulbifera L.. Diosbulbin C possesses high anticancer activity in non-small cell lung cancer (NSCLC). Diosbulbin C could induce cell cycle arrest at G0/G1 phase in NSCLC. Diosbulbin C also inhibits the proliferation of NSCLC cells, possibly by downregulating the expression/activation of AKT, DHFR, and TYMS .

HY-Y0106R

2,6-Dihydroxyacetophenone (Standard)	Structural Classification Ketones, Aldehydes, Acids Phenols Polyphenols Endogenous metabolite Source Classification	Reference Standards mTOR Xanthine Oxidase Apoptosis
2,6-Dihydroxyacetophenone (Standard) is the analytical standard of 2,6-Dihydroxyacetophenone (HY-Y0106). This product is intended for research and analytical applications. 2,6-Dihydroxyacetophenone, a polyphenolic derivative of Acetophenone (HY-Y0989), is an orally active mTOR inhibitor. 2,6-Dihydroxyacetophenone shows antioxidant activity. 2,6-Dihydroxyacetophenone inhibits cell growth and proliferation in CRC cells. 2,6-Dihydroxyacetophenone arrests at G0/G1 phase of cell cycle, induces apoptosis and suppresses cell migration in CRC cells. 2,6-Dihydroxyacetophenone inhibits xanthine oxidase (XOD) with an IC₅₀ of 1.24 mM. 2,6-dihydroxyacetophenone improves uric acid metabolism in hyperuricemia mice, reduces plasma cholesterol in hypercholesterolemic rats, and inhibits lipid accumulation in HFD-induced obese mice. 2,6-Dihydroxyacetophenone can be used for the study of colorectal cancer (CRC), hyperuricemia and hypercholesterolemia .

HY-N18190

N-Desmethyldauricine	Structural Classification Alkaloids Plants Isoquinoline Alkaloids Menispermaceae Menispermum dauricum Source Classification	NF-κB Apoptosis
N-Desmethyldauricine is a NF-κB p65 inhibitor and apoptosis inducer. N-Desmethyldauricine reduces the protein expression level of p65, induces apoptosis, arrests the cell cycle at the G0/G1 phase, attenuates intercellular adhesion, and inhibits the growth of 3D spheroids of triple-negative breast cancer. N-Desmethyldauricine can be used in studies related to triple-negative breast cancer .

HY-N7844R

N6-Benzyladenosine (Standard) Benzyladenosine (Standard)	Natural Products Umbelliferae Plants Eupatorium buniifolium Hook. & Arn. Source Classification	Apoptosis Adenosine Receptor Phytohormone Reference Standards
N6-Benzyladenosine (Standard) (Benzyladenosine (Standard)) is the analytical standard of N6-Benzyladenosine (HY-N7844). This product is intended for research and analytical applications. N6-Benzyladenosine is an adenosine receptor agonist, has a cytoactive activity. N6-Benzyladenosine arrests cell cycle at G0/G1 phase and induces cell apoptosis. N6-Benzyladenosine also exerts inhibitory effect on T. gondii adenosine kinase and glioma - .

Cat. No.	Product Name	Chemical Structure

HY-N7844S

N6-Benzyladenosine-d5
N6-Benzyladenosine-d₅ (Benzyladenosine-d₅) is deuterium labeled N6-Benzyladenosine. N6-Benzyladenosine is an adenosine receptor agonist, has a cytoactive activity. N6-Benzyladenosine arrests cell cycle at G0/G1 phase and induces cell apoptosis. N6-Benzyladenosine also exerts inhibitory effect on T. gondii adenosine kinase and glioma .

Cat. No.	Product Name		Classification

HY-152263

HEMTAC CDK4/6 degrader 1		PROTAC Synthesis
HEMTAC CDK4/6 degrader 1 is a PROTAC connected by ligands for HSP90 and CDK4/6 with a K_d value of 35.7 μM. HEMTAC CDK4/6 degrader 1 induces CDK4/6 degradation in B16F10 melanoma cells. HEMTAC CDK4/6 degrader 1 arrests cell cycle at G0/G1 phase and induces apoptosis. HEMTAC CDK4/6 degrader 1 can be used in research of cancer . HEMTAC CDK4/6 degrader 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-159519

EGFR/HER2-IN-16		Azide
EGFR/HER2-IN-16 (compound 12K) is an effective dual-target inhibitor of EGFR (IC₅₀=6.15 nM) and HER-2 (IC₅₀=9.78 nM) with anti-tumor activity. EGFR/HER2-IN-16 can inhibit the migration of SK-BR-3 cells, arrest the cell cycle in the G0/G1 phase, and induce apoptosis. EGFR/HER2-IN-16 exhibits good anti-proliferative activity against tumor cell models and has little damage to healthy cells. EGFR/HER2-IN-16 can be used in breast cancer research .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

G0/G1 phase cell-cycle arrest

Inhibitors & Agonists

Peptides

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

Natural
Products